» Articles » PMID: 38729995

Comprehensive Genomic and Transcriptomic Characterization of High-grade Gastro-entero-pancreatic Neoplasms

Abstract

Background: High-grade gastro-entero-pancreatic neoplasms (HG GEP-NENs) can be stratified according to their morphology and Ki-67 values into three prognostic classes: neuroendocrine tumors grade 3 (NETs G3), neuroendocrine carcinomas with Ki-67 < 55% (NECs <55) and NECs with Ki-67 ≥ 55% (NECs ≥55).

Methods: We analyzed a cohort of 49 HG GEP-NENs by targeted Next-Generation Sequencing (TrueSight Oncology 500), RNA-seq, and immunohistochemistry for p53, Rb1, SSTR-2A, and PD-L1.

Results: Frequent genomic alterations affected TP53 (26%), APC (20%), KRAS and MEN1 (both 11%) genes. NET G3 were enriched in MEN1 (p = 0.02) mutations, while both NECs groups were enriched in TP53 (p = 0.001), APC (p = 0.002) and KRAS (p = 0.02) mutations and tumors with TMB ≥ 10 muts/Mb (p = 0.01). No differentially expressed (DE) gene was found between NECs <55% and NECs ≥55%, while 1129 DE genes were identified between NET G3 and NECs. A slight enrichment of CD4 and CD8 T cells in NECs and of cancer-associated fibroblasts and macrophages (M2-like) in NET G3. Multivariate analysis identified histologic type and Rb1 loss as independent prognostic factors for overall survival.

Conclusions: This study showed that GEP-NET G3 and GEP-NECs exhibit clear genomic and transcriptomic differences, differently from GEP-NECs <55% and GEP-NECs ≥55%, and provided molecular findings with prognostic and potentially predictive value.

Citing Articles

[Neuroendocrine carcinomas of the gastrointestinal tract : Morphology, molecular pathology, cellular origin].

Jesinghaus M Pathologie (Heidelb). 2024; 45(Suppl 1):8-13.

PMID: 39535611 DOI: 10.1007/s00292-024-01386-7.


Potential neuroendocrine differentiation in poorly differentiated colorectal adenocarcinoma: A hidden trait?.

Rong Y, Kato I, Okubo N, Tsuyuki S, Katsuta E, Kobayashi N Mol Clin Oncol. 2024; 21(6):91.

PMID: 39421232 PMC: 11484215. DOI: 10.3892/mco.2024.2789.


Aberrant positivity for BCOR immunohistochemistry in merkel cell carcinoma - a potential diagnostic pitfall.

Vetter V, Haberecker M, Huber F, Pauli C Diagn Pathol. 2024; 19(1):130.

PMID: 39334415 PMC: 11437883. DOI: 10.1186/s13000-024-01552-8.

References
1.
Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B . ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016; 103(2):186-94. DOI: 10.1159/000443172. View

2.
Pavel M, Oberg K, Falconi M, Krenning E, Sundin A, Perren A . Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7):844-860. DOI: 10.1016/j.annonc.2020.03.304. View

3.
Sorbye H, Welin S, Langer S, Vestermark L, Holt N, Osterlund P . Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2012; 24(1):152-60. DOI: 10.1093/annonc/mds276. View

4.
Frizziero M, Wang X, Chakrabarty B, Childs A, Luong T, Walter T . Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. World J Gastroenterol. 2019; 25(39):5991-6005. PMC: 6815794. DOI: 10.3748/wjg.v25.i39.5991. View

5.
Heetfeld M, Chougnet C, Olsen I, Rinke A, Borbath I, Crespo G . Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015; 22(4):657-64. DOI: 10.1530/ERC-15-0119. View